InsiderTrades.com logo
We recommended Palantir in 2021, now we’re recommending this...
From Behind the Markets   |   Ad
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
Click to get the name and ticker symbol

Tsontcho Ianchulev Biography and Net Worth

CEO of Eyenovia
  • LinkedIn
  • Phone
  • Email
  • Website


Dr. Ianchulev has been serving as our Chief Executive Officer, Chief Medical Officer and a member of our Board of Directors since March 2014. From 2009 to 2016, he was the chief medical officer and the head of technology and business development for Transcend Medical, Inc. (acquired by Novartis International AG/Alcon, Inc. (NYSE: NVS)). Prior to that, while at Genentech, Inc. (NYSE: DNA, before going private in 2009), Dr. Ianchulev headed the ophthalmology research group and directed the development and the FDA approval of Lucentis. Dr. Ianchulev currently serves as a director of the ASCRS Foundation, and is a member of the Board of Directors of Iantrek, Inc. and AEye, Inc. He was formerly chairman of the board of directors of ianTECH from 2014 until its acquisition by Carl Zeiss Meditec AG (ETR: AFX) in 2019. Dr. Ianchulev received his B.S. from the University of Rochester. He received both his M.D. and an M.P.H. from Harvard University and completed his specialty training at the Doheny Eye Institute. Currently, Dr. Ianchulev serves as a professor in the New York Eye and Ear Infirmary of Mount Sinai.

What is Tsontcho Ianchulev's net worth?

The estimated net worth of Tsontcho Ianchulev is at least $28,252.30 as of May 1st, 2023. Dr. Ianchulev owns 331,211 shares of Eyenovia stock worth more than $28,252 as of December 22nd. This net worth approximation does not reflect any other assets that Dr. Ianchulev may own. Additionally, Dr. Ianchulev receives a salary of $167,500.00 as CEO at Eyenovia. Learn More about Tsontcho Ianchulev's net worth.

How old is Tsontcho Ianchulev?

Dr. Ianchulev is currently 50 years old. There are 3 older executives and no younger executives at Eyenovia. The oldest executive at Eyenovia is Mr. John P. Gandolfo CPA, CFO & Secretary, who is 63 years old. Learn More on Tsontcho Ianchulev's age.

What is Tsontcho Ianchulev's salary?

As the CEO of Eyenovia, Inc., Dr. Ianchulev earns $167,500.00 per year. There are 3 executives that earn more than Dr. Ianchulev. The highest earning executive at Eyenovia is Mr. Michael M. Rowe, CEO & Director, who commands a salary of $775,470.00 per year. Learn More on Tsontcho Ianchulev's salary.

How do I contact Tsontcho Ianchulev?

The corporate mailing address for Dr. Ianchulev and other Eyenovia executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Eyenovia can also be reached via phone at (917) 289-1117 and via email at [email protected]. Learn More on Tsontcho Ianchulev's contact information.

Has Tsontcho Ianchulev been buying or selling shares of Eyenovia?

Tsontcho Ianchulev has not been actively trading shares of Eyenovia in the last ninety days. Most recently, Tsontcho Ianchulev sold 90,000 shares of the business's stock in a transaction on Monday, May 1st. The shares were sold at an average price of $5.50, for a transaction totalling $495,000.00. Following the completion of the sale, the director now directly owns 331,211 shares of the company's stock, valued at $1,821,660.50. Learn More on Tsontcho Ianchulev's trading history.

Who are Eyenovia's active insiders?

Eyenovia's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Eyenovia's active insiders.

Are insiders buying or selling shares of Eyenovia?

In the last twelve months, Eyenovia insiders bought shares 6 times. They purchased a total of 1,752,939 shares worth more than $1,219,009.44. The most recent insider tranaction occured on August, 28th when CEO Michael M Rowe bought 27,071 shares worth more than $14,076.92. Insiders at Eyenovia own 7.1% of the company. Learn More about insider trades at Eyenovia.

Information on this page was last updated on 8/28/2024.

Tsontcho Ianchulev Insider Trading History at Eyenovia

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/1/2023Sell90,000$5.50$495,000.00331,211View SEC Filing Icon  
4/27/2023Sell60,000$5.00$300,000.00421,211View SEC Filing Icon  
4/14/2023Sell40,000$4.50$180,000.00481,211View SEC Filing Icon  
4/11/2023Sell40,000$4.00$160,000.00521,211View SEC Filing Icon  
3/31/2023Sell40,000$3.50$140,000.00561,211View SEC Filing Icon  
11/3/2021Buy30,000$4.04$121,200.00View SEC Filing Icon  
3/24/2020Buy82,431$2.27$187,118.37508,679View SEC Filing Icon  
7/11/2019Buy233,813$2.78$650,000.14View SEC Filing Icon  
6/28/2018Buy6,000$6.63$39,780.00View SEC Filing Icon  
See Full Table

Tsontcho Ianchulev Buying and Selling Activity at Eyenovia

This chart shows Tsontcho Ianchulev's buying and selling at Eyenovia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eyenovia Company Overview

Eyenovia logo
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $0.09
Low: $0.08
High: $0.09

50 Day Range

MA: $0.29
Low: $0.08
High: $0.57

2 Week Range

Now: $0.09
Low: $0.08
High: $2.57

Volume

14,142,422 shs

Average Volume

3,200,527 shs

Market Capitalization

$7.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43
We recommended Palantir in 2021, now we’re recommending this...
From Behind the Markets   |   Ad
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
Click to get the name and ticker symbol